Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80.
The study examined the antiparkinsonian effect of nerve growth factor adsorbed on the surface of polybutylcyanoacrylate nanoparticles coated with polysorbate-80 surfactant. The parkinsonian syndrome in C57B1/6 mice was provoked by intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. The basic symptoms of the parkinsonian syndrome decreased under the action of the nerve growth factor adsorbed on nanoparticles coated with polysorbate-80, which was seen from decreased rigidity and increased locomotor activity compared to control mice receiving with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine alone. This effect of nerve growth factor on nanoparticles persisted after 7 and 21 days after single injection of the neurotoxin. These data attest to the possibility of using nanoparticles prepared from amphiphilic polymers and coated with polysorbate-80 for the delivery of nerve growth factor into the brain during systemic treatment.
Kurakhmaeva
K B
KB
V. V. Zakusov State Research Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow.
Voronina
T A
TA
Kapica
I G
IG
Kreuter
J
J
Nerobkova
L N
LN
Seredenin
S B
SB
Balabanian
V Yu
VY
Alyautdin
R N
RN
D000327:Adsorption; D000818:Animals; D000978:Antiparkinson Agents / Q000378:metabolism / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000378:metabolism; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism; D004659:Enbucrilate / Q000737:chemistry*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000502:physiology; D053758:Nanoparticles; D020932:Nerve Growth Factor / Q000378:metabolism / Q000627:therapeutic use*; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D011136:Polysorbates / Q000737:chemistry / Q000378:metabolism*; D013501:Surface-Active Agents / Q000737:chemistry / Q000378:metabolism
D000978:Antiparkinson Agents; D004337:Drug Carriers; D011136:Polysorbates; D013501:Surface-Active Agents; D020932:Nerve Growth Factor; D004659:Enbucrilate